TNFRSF9 and neoplasm: In a recent study, Kamata-Sakurai and colleagues demonstrated that extracellular ATP could be exploited to activate anti-tumoral therapeutics such as an anti-CD137 antibody only in the tumor milieu, thus increasing their tumor-suppressing activity while reducing unwanted systemic side effects [66].